In the realm of fibrotic diseases treatment, a promising avenue involves exploring combination therapies that integrate antifibrotic drugs with anti-inflammatory agents. This strategic approach aims to harness synergistic effects, addressing both fibrosis and inflammation concurrently to enhance treatment outcomes. Fibrotic diseases, including conditions such as idiopathic pulmonary fibrosis (IPF), often exhibit intertwined pathways involving fibrosis and inflammation. By combining therapeutic modalities, researchers seek to disrupt this complex interplay, potentially mitigating disease progression more effectively. This innovative strategy reflects a nuanced understanding of the multifaceted nature of fibrotic diseases, presenting a hopeful direction for the development of comprehensive and targeted treatment approaches.
According to Data Bridge Market Research analyses the Global Fibrotic Diseases Treatment Market will grow at a CAGR of 7.0% during the forecast period of 2023 to 2030.
"Rise in smoking cigarette boosts the market growth"
The rise in cigarette smoking contributes to a growing patient pool for fibrotic diseases, notably idiopathic pulmonary fibrosis (IPF). Smoking is a recognized risk factor for the development and progression of IPF, leading to more severe cases that require advanced treatment options. This phenomenon presents unique challenges, stimulating research initiatives to understand the link between smoking and fibrotic diseases. The focus on oxidative stress management in smoking-related IPF cases opens avenues for innovative therapies. Additionally, the global nature of smoking-related fibrotic diseases extends the market reach for pharmaceutical companies.
What restraints the growth of the global fibrotic diseases treatment market?
“High treatment cost hinders the market growth”
The escalating costs of fibrotic disease treatments pose a significant restraint on the fibrotic diseases treatment market. The surge in patients afflicted with fibrosis, coupled with increased prices of medical devices and medications, has contributed to a substantial rise in overall treatment expenses. This financial burden limits accessibility for patients and strains healthcare systems.
Segmentation: Global Fibrotic Diseases Treatment Market
The global fibrotic diseases treatment market is segmented on the basis of treatment, application, end-user, and distribution channel.
- On the basis of treatment, the global fibrotic diseases treatment market is segmented into medication, organ transplantation, oxygen therapy, and others
- On the basis of application, the global fibrotic diseases treatment market is segmented into idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others
- On the basis of end-user, the global fibrotic diseases treatment market is segmented into hospitals, specialty clinics, academic and research institutes, and others
- On the basis of distribution channel, the global fibrotic diseases treatment market is segmented into hospital pharmacy, retail pharmacy, and others
Regional Insights: Asia-Pacific is expected to dominate the Global Fibrotic Diseases Treatment Market
Asia-Pacific is expected to dominate due to its rapid adoption of new technologies, robust innovation ecosystems, and widespread use of mobile technology. Government initiatives, investments in infrastructure, and favorable regulatory environments support digital transformation efforts while emerging startup hubs contribute to regional innovation. The region's excellence in healthcare, biotechnology, and advanced manufacturing, particularly in countries such as China and Japan, further solidifies its global leadership in technological advancements.
To know more about the study visit, https://www.databridgemarketresearch.com/fr/reports/globalfibroticdiseasestreatmentmarket
Recent Developments in the Global Fibrotic Diseases Treatment Market
- In May 2022, Boehringer Ingelheim, a prominent biopharmaceutical company, and ArisGlobal, a global leader in drug safety solutions, jointly revealed the acquisition of Boehringer Ingelheim's digital innovation, BRASS, by ArisGlobal. This data insights engine has been seamlessly integrated into ArisGlobal's LifeSphere technology platform, rebranded as LifeSphere Clarity. This strategic move is poised to significantly advance pharmacovigilance and patient safety on an industrywide scale. The acquisition has not only propelled the expansion of Boehringer Ingelheim's clinical diagnostics business globally but has also enhanced its overall presence in the market
- In March 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced the completion of a definitive merger agreement, with Bristol Myers Squibb acquiring Turning Point Therapeutics for USD 76.00 per share. Unanimously approved by both companies' Boards of Directors, the transaction was set to conclude in the third quarter of 2022. This acquisition marks a strategic move for Bristol Myers Squibb, strengthening its global market presence. The incorporation of Turning Point Therapeutics into the company's portfolio is anticipated to contribute significantly to its position in the market, fostering growth and innovation in the pharmaceutical sector
The Prominent Key Players Operating in the Global Fibrotic Diseases Treatment Market Include:
- Genentech, Inc. (U.S.)
- C.H. Boehringer Ingelheim International GmbH (Germany)
- AbbVie Inc. (U.S.)
- Redx Pharma Plc (U.K.)
- BristolMyers Squibb Company (U.S.)
- BellBrook Labs (U.S.)
- Enveda Biosciences (U.S.)
- BioMX (Israel)
- Gilead Sciences, Inc. (U.S.)
- KITHER BIOTECH S.R.L. (Italy)
- Verona Pharma plc (U.K.)
- Alpine Immune Sciences (U.S.)
- Intercept Pharmaceuticals, Inc. (U.S.)
- Pharmaxis Ltd (Australia)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sandoz International GmbH (Germany)
- Accord Healthcare (U.K.)
- Camber Pharmaceuticals, Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of global fibrotic diseases treatment market companies contact, https://www.databridgemarketresearch.com/fr/contact
Research Methodology: Global Fibrotic Diseases Treatment Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
